IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; and MRI compatible patient vital signs monitoring system. The company also offers IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. It serves hospitals, acute care facilities, and outpatient imaging centers. The company sells its products through direct field sales representatives, regional sales directors, clinical support representatives, and independent distributors. IRADIMED CORPORATION was incorporated in 1992 and is headquartered in Winter Springs, Florida.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Phone407-677-8022
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$30.44 million
Profitability
Miscellaneous
Employees95
Next Earnings Date4/30/2019 (Confirmed)
OptionableNot Optionable
Iradimed (NASDAQ:IRMD) Frequently Asked Questions
What is Iradimed's stock symbol?
Iradimed trades on the NASDAQ under the ticker symbol "IRMD."
How will Iradimed's stock buyback program work?
Iradimed announced that its Board of Directors has authorized a stock buyback program on Sunday, June 4th 2017, which permits the company to buyback $8,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization permits the company to buy shares of its stock through open market purchases. Shares buyback programs are often a sign that the company's management believes its shares are undervalued.
How were Iradimed's earnings last quarter?
Iradimed Corp (NASDAQ:IRMD) posted its quarterly earnings data on Wednesday, February, 6th. The medical equipment provider reported $0.14 earnings per share for the quarter, beating the consensus estimate of $0.13 by $0.01. The medical equipment provider had revenue of $8.34 million for the quarter, compared to analysts' expectations of $8.19 million. Iradimed had a net margin of 20.71% and a return on equity of 13.78%. View Iradimed's Earnings History.
When is Iradimed's next earnings date?
What guidance has Iradimed issued on next quarter's earnings?
Iradimed updated its first quarter 2019 earnings guidance on Wednesday, February, 6th. The company provided EPS guidance of $0.12-0.13 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.15. The company issued revenue guidance of $8.3-8.5 million, compared to the consensus revenue estimate of $9.1 million.Iradimed also updated its guidance to EPS.
What price target have analysts set for IRMD?
1 brokers have issued 12 month target prices for Iradimed's stock. Their forecasts range from $35.00 to $35.00. On average, they expect Iradimed's share price to reach $35.00 in the next twelve months. This suggests a possible upside of 28.0% from the stock's current price. View Analyst Price Targets for Iradimed.
What is the consensus analysts' recommendation for Iradimed?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iradimed in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Iradimed.
Has Iradimed been receiving favorable news coverage?
News stories about IRMD stock have trended positive recently, InfoTrie reports. InfoTrie scores the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Iradimed earned a daily sentiment score of 2.7 on InfoTrie's scale. They also assigned press coverage about the medical equipment provider a news buzz of 1.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the immediate future.
Who are some of Iradimed's key competitors?
Some companies that are related to Iradimed include Cardiovascular Systems (CSII), AtriCure (ATRC), Orthofix Medical (OFIX), Cryolife (CRY), Luminex (LMNX), Tactile Systems Technology (TCMD), Intersect ENT (XENT), Shockwave Medical (SWAV), Cerus (CERS), AngioDynamics (ANGO), OraSure Technologies (OSUR), SurModics (SRDX), LeMaitre Vascular (LMAT), Axonics Modulation Technologies (AXNX) and Orthopediatrics (KIDS).
What other stocks do shareholders of Iradimed own?
Who are Iradimed's key executives?
Iradimed's management team includes the folowing people:
- Mr. Roger E. Susi, Founder, Chairman, CEO & Pres (Age 66)
- Mr. Christopher K. Scott, CFO & Sec. (Age 49)
- Mr. John McCreery, Chief Operating Officer (Age 64)
- Mr. Brent Johnson, Exec. VP of Worldwide Sales & Marketing (Age 60)
- Mr. Louis Waldman, Controller (Age 64)
How do I buy shares of Iradimed?
Shares of IRMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Iradimed's stock price today?
One share of IRMD stock can currently be purchased for approximately $27.35.
How big of a company is Iradimed?
Iradimed has a market capitalization of $300.77 million and generates $30.44 million in revenue each year. The medical equipment provider earns $6.30 million in net income (profit) each year or $0.43 on an earnings per share basis. Iradimed employs 95 workers across the globe.
What is Iradimed's official website?
How can I contact Iradimed?
Iradimed's mailing address is 1025 Willa Springs Dr., Winter Springs FL, 32708. The medical equipment provider can be reached via phone at 407-677-8022 or via email at [email protected]
MarketBeat Community Rating for Iradimed (NASDAQ IRMD)
MarketBeat's community ratings are surveys of what our community members think about Iradimed and other stocks. Vote "Outperform" if you believe IRMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IRMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
